61 results
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
or strategic partnership;
retention of key employees, the loss of key personnel, and uncertainties in Ocuphire’s ability to maintain key business
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
Act of 1977), which payment, receipt or retention of funds is of a character required to be disclosed in the Registration Statement or the Prospectus
8-K
EX-10.1
a7kd2g vgymyty5
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
424B5
hte36gn4
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
fz3pitoguwvxkefpm
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K/A
EX-1.1
3b7s is4pze23
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-1.1
p8ysv9oiogk b9
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
8-K
EX-10.1
o7xu06 bjcf
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
mbu384azatae
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-1.1
dt6bci8vd5m27 i7k02z
11 Mar 21
Entry into a Material Definitive Agreement
8:34am